transmembrane and immunoglobulin domain containing 1Genealiases: TMIGD · UNQ9372
Q-omics provides the consensus-scored TMIGD1 profile across patient tissues and cancer cell-line models. TMIGD1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMIGD1 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, TMIGD1 RNA expression shows 6,769 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, COAD, and STAD as cancer lineages where TMIGD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMIGD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMIGD1 survival associations across molecular data types. TMIGD1 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMIGD1 RNA expression–survival associations across cancer types. High TMIGD1 expression shows unfavorable associations in ACC, UCEC, THCA, LIHC and BRCA, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMIGD1 RNA expression.
This table summarizes TMIGD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TMIGD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMIGD1 shows lower tumor expression in COAD, KIRP, READ and KICH and higher tumor expression in LIHC and HNSC. The COAD box plot shows higher TMIGD1 RNA expression in normal versus tumor tissue (log2 FC = −6.326, t-test p < 0.001).
This table shows molecular features associated with TMIGD1 in patient tissues and cancer cell lines. In patient samples, TMIGD1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TMIGD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
